Uncoupling the pro- and anti-tumorigenic effects of extracellular targets and membrane receptors of eHSP70 and selectively inhibiting their pathological activity can allow us to develop and assess HSP70-based anti-cancer therapies with greater clinical efficacies. Here, HSPA1A is linked to cancer.